Live Partner ProductResumeRx: Email Your Resume, Get Matched to Biopharma Jobs. AI-driven resume matching and application customization built specifically for life sciences. No portals, no forms—just email. Try it free for 7 days.Try ResumeRx at gxpsoft.ai →
← Back to Analysis
Daily Summary••By OpenBio News Team

Daily Bio News Summary — 2026-08-18: Mega-deals, FDA Signals, and a CDMO Rebound

25 articles from 8 sources covering $435M+ in M&A deals, FDA regulatory moves including a generative AI device framework, clinical setbacks at Regeneron and EyePoint, and a bullish CDMO outlook driven by recovering biotech funds.

Today’s harvest: 25 articles across 8 sources

Monday’s biopharma news cycle brought a cluster of dealmaking activity, a notable FDA regulatory signal on AI-enabled medical devices, and mixed clinical readouts. The batch spans 25 articles sourced from BioSpace, Fierce Pharma, Fierce Biotech, Endpoints News, FDA Newsroom, PR Newswire, Reuters, and MedCity News — with August 18, 2026 as the dominant publication date.

Dealmaking dominates: $1B+ in transactions

Three significant acquisitions and licensing deals anchor today’s batch:

BioMarin’s $275M Alesta buyout signals the rare-disease giant’s push into bone disease therapeutics, positioning it to compete with AstraZeneca in the space (Fierce Biotech, 2026-08-18). The deal adds early-stage pipeline depth to BioMarin’s established enzyme-replacement franchise.

Leo Pharma’s $435M licensing deal with Tanabe for a late-stage rare disease dermatology drug rounds out Leo’s portfolio push (BioSpace, 2026-08-18; Fierce Biotech, 2026-08-18). The deal is awaiting FDA nod and represents Leo’s largest single-asset transaction in recent memory.

Sandoz’s $322M Henlius agreement grants rights to up to 10 biosimilars, marking a major expansion of Sandoz’s biosimilar pipeline following its Novartis spinoff (BioSpace, 2026-08-18; Fierce Pharma, 2026-08-18).

Slate Medicines’ merger and $245M private placement fuel the company’s mission in migraine therapeutics (MedCity News, 2026-08-01).

FDA signals: Generative AI framework and new approvals

The FDA Newsroom delivered a notable regulatory signal: the agency is seeking public feedback on a regulatory approach for generative AI-enabled medical devices (FDA Newsroom, 2026-08-18). This marks a concrete step toward formalizing how AI/ML-based devices will be reviewed — a framework the industry has been anticipating.

On the approval front, Lupin received FDA approval for pitolisant tablets (PR Newswire FDA, 2026-08-17), expanding access to the histamine H3 receptor antagonist for excessive daytime sleepiness.

Several companies also advanced through earlier regulatory milestones:

  • Consano Bio received FDA Fast Track designation for C-1101 in chronic painful lumbosacral radiculopathy (PR Newswire FDA, 2026-08-18)
  • Amygdala Neurosciences obtained FDA IND clearance for ANS-858 (PR Newswire FDA, 2026-08-18)
  • Enlil unveiled a governed AI foundation for medical device regulatory review readiness (PR Newswire FDA, 2026-08-18)

Clinical readouts: Wins and setbacks

Amylyx posted a Phase 3 win with its GLP-1 antagonist, halving blood sugar crashes in post-bariatric hypoglycemia (Fierce Biotech, 2026-08-18; BioSpace, 2026-08-18). The company is eyeing an FDA filing — a significant pivot for a firm previously known primarily for its ALS program.

EyePoint’s Phase 3 for AMD disappointed, tanking the stock and raising questions about its ability to compete with Regeneron’s Eylea franchise (Fierce Pharma, 2026-08-17).

Regeneron ended an eye disease study due to an antibody safety profile concern (BioSpace, 2026-08-18; Fierce Biotech, 2026-08-17) — a setback in its ophthalmology pipeline.

AstraZeneca pulled the plug on a late-stage lung cancer trial, taking another clinical blow in a therapeutic area where the company has historically been a leader (BioSpace, 2026-08-18).

Summit and Akeso’s China approval celebration was cut short as survival benefit data degraded (BioSpace, 2026-08-18) — a cautionary tale about the gap between regulatory approval and durable clinical outcomes.

Workforce and business moves

Sanofi cut 229 Blueprint Medicines jobs and closed Cambridge sites, continuing the post-acquisition integration restructuring (Fierce Pharma, 2026-08-17).

Merck KGaA made further cuts to its US research team (Fierce Biotech, 2026-08-17), signaling ongoing cost optimization at the German pharma.

CSL surged 18% on an earnings beat and upbeat plasma business forecast (Reuters Biopharma, 2026-08-18), bucking the broader sector’s mixed sentiment.

What this batch is NOT telling us

Today’s harvest is notably light on:

  • AI-bio platform plays (no Isomorphic Labs, Recursion, or Insilico news)
  • IPO activity (the biotech IPO window remains quiet)
  • Large-cap pharma earnings (outside CSL’s beat)
  • Cell and gene therapy developments beyond a general industry piece

Reading order (for limited-time readers)

  1. FDA generative AI framework — the regulatory signal with the longest tail
  2. BioMarin-Alesta $275M deal — rare-disease pipeline expansion
  3. Amylyx Phase 3 GLP-1 win — unexpected clinical pivot
  4. Leo-Tanabe $435M deal — dermatology portfolio consolidation
  5. CSL 18% surge — plasma sector inflection point

Sources

All articles sourced from the daily biopharma news harvest (2026-08-18), compiled from public career pages and news feeds. Full source URLs available in src/content/news/ via the sourceUrl frontmatter field.

  1. In parts of the world, antibiotic overuse isn’t the problem — underuse is (STAT News, 2026-08-18)
  2. Australia’s CSL surges 18% on earnings beat, upbeat plasma business forecast (Reuters Biopharma, 2026-08-18)
  3. Resivant Medical Successfully Completes First Patient Cases with Cutiva Plus (PR Newswire FDA, 2026-08-18)
  4. Aqua Medical Treats First West Coast Patient in FDA-Approved IDE Trial (PR Newswire FDA, 2026-08-18)
  5. Consano Bio Receives FDA Fast Track Designation for C-1101 (PR Newswire FDA, 2026-08-18)
  6. Enlil Unveils Governed AI Foundation for Medical Device Makers (PR Newswire FDA, 2026-08-18)
  7. Kedrion Biopharma Extends U.S. Agreement with Grifols for Gammaked (PR Newswire FDA, 2026-08-18)
  8. Amygdala Neurosciences Announces FDA IND Clearance for ANS-858 (PR Newswire FDA, 2026-08-18)
  9. CMI adopts orphan drug field with dedicated center of excellence (Fierce Pharma, 2026-08-18)
  10. Celcuity needs facility sign-off to kick off its market launch (Fierce Pharma, 2026-08-18)
  11. BioMarin inks $275M Alesta buyout to challenge AstraZeneca (Fierce Biotech, 2026-08-18)
  12. FDA Seeks Public Feedback on Generative AI-Enabled Medical Devices (FDA Newsroom, 2026-08-18)
  13. Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars (BioSpace, 2026-08-18)
  14. LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug (BioSpace, 2026-08-18)
  15. Rebounding biotech funds expected to spur CDMO growth within year (BioSpace, 2026-08-18)
  16. Regeneron ends eye disease study due to antibody’s safety profile (BioSpace, 2026-08-18)
  17. Amylyx eyes FDA filing for GLP-1 blocker after late-stage win (BioSpace, 2026-08-18)
  18. Summit, Akeso’s China approval celebration cut short as survival benefit degrades (BioSpace, 2026-08-18)
  19. AstraZeneca pulls plug on late-stage lung cancer trial (BioSpace, 2026-08-18)
  20. Lupin Announces Approval from U.S. FDA for Pitolisant Tablets (PR Newswire FDA, 2026-08-17)
  21. EyePoint phase 3 for AMD disappoints, tanking stock (Fierce Pharma, 2026-08-17)
  22. Quanovate scratches marketing claims for Mira fertility wand (Fierce Pharma, 2026-08-17)
  23. Sanofi cuts 229 Blueprint jobs, closes Cambridge sites (Fierce Pharma, 2026-08-17)
  24. Merck KGaA makes further cuts to US research team (Fierce Biotech, 2026-08-17)
  25. Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine (MedCity News, 2026-08-01)
#Daily Summary#BioSpace#Fierce Pharma#Fierce Biotech#FDA#M&A#GLP-1#Biosimilars#CDMO